Share This Article:

Urinary Bladder Cancer: The Current and Potential Role of MR Imaging in Non-Distant Metastatic Lesions

Abstract Full-Text HTML XML Download Download as PDF (Size:328KB) PP. 504-512
DOI: 10.4236/jct.2013.42062    4,094 Downloads   6,317 Views  

ABSTRACT

Urinary bladder cancer is the second most common genitourinary malignancy in Westernized countries. A number of emerging imaging techniques have recently been reported in the literature for use in imaging bladder cancer. While the explicit application of MR imaging in bladder cancer especially in non-distant bladder cancer or bladder cancer localized in pelvic remains uncertain and awaits a thorough evaluation. Therefore, this article aims to make a systematic review of previous literature and provide a complete assessment of the value of MR as an evolving imaging tool in localized urinary bladder cancer application. Studies were conducted by searching the MEDLINE and PubMed databases up to 2012 using both medical subject heading (Mesh) and a free text method like “urinary bladder cancer”, “magnetic resonance imaging” or “MRI”, “diffusion weighted imaging” or “DWI”. About 53 articles were selected and analyzed which were considered to be associated with the objective of this systematic review (Table 1). Results showed that MRI especially the newer functional imaging technique like DWI may has a great potential role in localized bladder cancer like early detection, staging, evaluation of tumor aggressiveness and therapeutic responsiveness of patients in the assessment of urinary bladder cancer and so forth. Newer MRI has already proceeded promising results in bladder cancer application; and the explicit role of newer MRI in bladder cancer patients still needs further research and awaits to be thoroughly evaluated.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

H. Wang, Y. Guo, X. Zhou and D. Yang, "Urinary Bladder Cancer: The Current and Potential Role of MR Imaging in Non-Distant Metastatic Lesions," Journal of Cancer Therapy, Vol. 4 No. 2, 2013, pp. 504-512. doi: 10.4236/jct.2013.42062.

References

[1] A. Saad, D. C. Hanbury, T. A. McNicholas, et al., “A Study Comparing Various Noninvasive Methods of Detecting Bladder Cancer in Urine,” BJUI International, Vol. 89, No. 4, 2002, pp. 369-373. doi:10.1046/j.1464-4096.2001.01699.x
[2] C. A. Sadow, S. G. Silverman, M. P. O’Leary, et al., “Bladder Cancer Detection with CT Urography in an Academic Medical Center,” Radiology, Vol. 249, No. 1, 2008, pp. 195-202. doi:10.1148/radiol. 2491071860
[3] J. I. Epstein, “The New World Health Organization/International Society of Urological Pathology (WHO/ISUP) Classification for TA, T1 Bladder Tumors: Is It an Improvement?” Critical Reviews in Oncology/Hematology, Vol. 47, No. 2, 2003, pp. 83-89.
[4] M. A. Amendola, G. M. Glazer, H. B. Grossman, et al., “Staging of Bladder Carcinoma: MRI-CT-Surgical Correlation,” American Journal of Roentgenology, Vol. 146, No. 6, 1986, pp. 1179-1183. doi:10.2214/ajr.146.6.1179
[5] W. Otto, S. Denzinger, H. M. Fritsche, et al., “The WHO Classification of 1973 Is More Suitable than the WHO Classification of 2004 for Predicting Survival in pT1 Urothelial Bladder Cancer,” BJUI International, Vol. 107, No. 3, 2011, pp. 404-408. doi:10.1111/j.1464-410X.2010.09515.x
[6] B. W. van Rhijn, M. Burger, Y. Lotan, et al., “Recurrence and Progression of Disease in Non-Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy,” European Urology, Vol. 56, No. 3, 2009, pp. 430-442. doi:10.1016/j.eururo.2009.06.028
[7] H. A. Frazier, J. E. Robertson and D. F. Paulson, “Complications of Radical Cystectomy and Urinary Diversion: A Retrospective Review of 675 Cases in 2 Decades,” Journal of Urology, Vol. 148, No. 5, 1992, pp. 1401-1405.
[8] C. T. Nguyen, A. J. Stephenson and M. W. Kattan, “Are Nomograms Needed in the Management of Bladder Cancer?” Urologic Oncology, Vol. 28, No. 1, 2010, pp. 102-107.
[9] C. L. Pashos, M. F. Botteman, B. L. Laskin, et al., “Bladder Cancer: Epidemiology, Diagnosis, and Management,” Cancer Practice, Vol. 10, No. 6, 2002, pp. 311-322. doi:10.1046/j.1523-5394.2002. 106011.x
[10] J. P. Stein, G. Lieskovsky, R. Cote, et al., “Radical Cystectomy in the Treatment of Invasive Bladder Cancer: LongTerm Results in 1054 Patients,” Journal of Clinical Oncology, Vol. 19, No. 3, 2001, pp. 666-675.
[11] S. Madersbacher, W. Hochreiter, F. Burkhard, et al., “Radical Cystectomy for Bladder Cancer Today—A Homogeneous Series without Neoadjuvant Therapy,” Journal of Clinical Oncology, Vol. 21, No. 4, 2003, pp. 690-696. doi:10.1200/JCO.2003.05.101
[12] S. F. Shariat, P. I. Karakiewicz, G. S. Palapattu, et al., “Outcomes of Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: A Contemporary Series from the Bladder Cancer Research Consortium,” Journal of Urology, Vol. 176, No. 6, 2006, pp. 2414-2422.
[13] J. J. Wong-You-Cheong, P. J. Woodward, M. A. Manning, et al., “From the Archives of the AFIP: Neoplasms of the Urinary Bladder: Radiologic-Pathologic Correlation,” Radiographics, Vol. 26, No. 2, 2006, pp. 553-580. doi:10.1148/rg.262055172
[14] M. K. Dighe, P. Bhargava and J. Wright, “Urinary Bladder Masses: Techniques, Imaging Spectrum, and Staging,” Journal of Computer Assisted Tomography, Vol. 35, No. 4, 2011, pp. 411-424. doi:10.1097/RCT.0b013e3 1821c2e9d
[15] J. Zhang, S. Gerst, R. A. Lefkowitz, et al., “Imaging of Bladder Cancer,” Radiologic Clinics of North America, Vol. 45, No. 1, 2007, pp. 183-205. doi:10.1016/j.rcl.2006.10.005
[16] A. Tekes, I. Kamel, K. Imam, et al., “Dynamic MRI of Bladder Cancer: Evaluation of Staging Accuracy,” American Journal of Roentgenology, Vol. 184, No. 1, 2005, pp. 121-127. doi:10.2214/ajr.184.1. 01840121
[17] Y. Narumi, T. Kadota, E. Inoue, et al., “Bladder Wall Morphology: In Vitro MR Imaging-Histopathologic Correlation,” Radiology, Vol. 187, No. 1, 1993, pp. 151-155.
[18] S. Venz, J. Ilg, T. Ebert, et al., “Determining the Depth of Infiltration in Urinary Bladder Carcinoma with Contrast Medium Enhanced Dynamic Magnetic Resonance Tomography. With Reference to Postoperative Findings and Inflammation,” Urologe A, Vol. 35, No. 4, 1996, pp. 297-304.
[19] J. O. Barentsz, G. J. Jager, P. B. van Vierzen, et al., “Staging Urinary Bladder Cancer after Transurethral Biopsy: Value of Fast Dynamic Contrast-Enhanced MR Imaging,” Radiology, Vol. 201, No. 1, 1996, pp. 185-193.
[20] A. R. Padhani, G. Liu, D. M. Koh, et al., “DiffusionWeighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations,” Neoplasia, Vol. 11, No. 2, 2009, pp. 102-125.
[21] D. M. Koh and D. J. Collins, “Diffusion-Weighted MRI in the Body: Applications and Challenges in Oncology,” American Journal of Roentgenology, Vol. 188, No. 6, 2007, pp. 1622-1635. doi:10.2214/AJR.06.1403
[22] M. R. Fisher, H. Hricak and E. A. Tanagho, “Urinary Bladder MR Imaging, Part II, Neoplasm,” Radiology, Vol. 157, No. 2, 1985, pp. 471-477.
[23] J. N. Buy, A. A. Moss, C. Guinet, et al., “MR Staging of Bladder Carcinoma: Correlation with Pathologic Findings,” Radiology, Vol. 169, No. 3, 1988, pp. 695-700.
[24] K. S. Rholl, J. K. Lee, J. P. Heiken, et al., “Primary Bladder Carcinoma: Evaluation with MR Imaging,” Radiology, Vol. 163, No. 1, 1987, pp. 117-121.
[25] N. Hayashi, H. Tochigi, T. Shiraishi, et al., “A New Staging Criterion for Bladder Carcinoma Using GadoliniumEnhanced Magnetic Resonance Imaging with an Endorectal Surface Coil: A Comparison with Ultrasonography,” BJUI International, Vol. 85, No. 1, 2000, pp. 32-36. doi:10.1046/j.1464-410x.2000.00358.x
[26] B. Kim, R. C. Semelka, S. M. Ascher, et al., “Bladder Tumor Staging: Comparison of Contrast-Enhanced CT, T1and T2-Weighted MR Imaging, Dynamic Gadolinium-Enhanced Imaging, and Late Gadolinium-Enhanced Imaging,” Radiology, Vol. 193, No. 1, 1994, pp. 239-245.
[27] M. Takeuchi, S. Sasaki, M. Ito, et al., “Urinary Bladder Cancer: Diffusion-Weighted MR Imaging—Accuracy for Diagnosing T Stage and Estimating Histologic Grade,” Radiology, Vol. 251, No. 1, 2009, pp. 112-121. doi:10.1148/radiol.2511080873
[28] M. A. Amendola, G. M. Glazer, H. B. Grossman, et al., “Staging of Bladder Carcinoma: MRI-CT-Surgical Correlation,” American Journal of Roentgenology, Vol. 146. No. 6, 1986, pp. 1179-1183. doi:10.2214/ajr.146.6.1179
[29] X. Tillou, E. Grardel, M. Fourmarier, et al., “Can MRI Be Used to Distinguish between superficial and Invasive Transitional Cell Bladder Cancer?” Progrès en Urologie, Vol. 18, No. 7, 2008, pp. 440-444. doi:10.1016/j.purol.2008.04.019
[30] R. B. Rafal and J. A. Markisz, “Urachal Carcinoma: The Role of Magnetic Resonance Imaging,” Urologic Radiology, Vol. 12, No. 4, 1991, pp. 184-187.
[31] A. Tanimoto, Y. Yuasa, Y. Imai, et al., “Bladder Tumor Staging: Comparison of Conventional and GadoliniumEnhanced Dynamic MR Imaging and CT,” Radiology, Vol. 185, No. 3, 1992, pp. 741-747.
[32] V. Scattoni, P. L. Da, R. Colombo, et al., “Dynamic Gadolinium-Enhanced Magnetic Resonance Imaging in Staging of Superficial Bladder Cancer,” Journal of Urology, Vol. 155, No. 5, 1996, pp. 1594-1599. doi:10.1016/S0022-5347(01)66139-1
[33] J. M. Neuerburg, K. Bohndorf, M. Sohn, et al., “Staging of Urinary Bladder Neoplasms with MR Imaging: Is GdDTPA Helpful?” Journal of Computer Assisted Tomography, Vol. 15, No. 5, 1991, pp. 780-786. doi:10.1097/00004728-199109000-00010
[34] A. Rajesh, H. K. Sokhi, R. Fung, et al., “Bladder Cancer: Evaluation of Staging Accuracy Using Dynamic MRI,” Clinical Radiology, Vol. 66, No. 12, 2011, pp. 1140-1145. doi:10.1016/j.crad.2011.05.019
[35] M. E. Abou-El-Ghar, A. El-Assmy, H. F. Refaie, et al., “Bladder Cancer: Diagnosis with Diffusion-Weighted MR Imaging in Patients with Gross Hematuria,” Radiology, Vol. 251, No. 2, 2009, pp. 415-421. doi:10.1148/radiol.2503080723
[36] H. Watanabe, M. Kanematsu, H. Kondo, et al., “Preoperative T Staging of Urinary Bladder Cancer: Does Diffusion-Weighted MRI Have Supplementary Value?” American Journal of Roentgenology, Vol. 192, No. 5, 2009, pp. 1361-1366. doi:10.2214/AJR.08.1430
[37] M. Matsuki, Y. Inada, F. Tatsugami, et al., “DiffusionWeighted MR Imaging for Urinary Bladder Carcinoma: Initial Results,” European Radiology, Vol. 17, No. 1, 2007, pp. 201-204. doi:10.1007/s00330-006-0281-7
[38] A. El-Assmy, M. E. Abou-El-Ghar, H. F. Refaie, et al., “Diffusion-Weighted MR Imaging in Diagnosis of Superficial and Invasive Urinary Bladder Carcinoma: A Preliminary Prospective Study,” Scientific World Journal, Vol. 8, 2008, pp. 364-370. doi:10.1100/tsw.2008.55
[39] D. M. Koh, T. Takahara, Y. Imai, et al., “Practical Aspects of Assessing Tumors Using Clinical DiffusionWeighted Imaging in the Body,” Magnetic Resonance in Medical Sciences, Vol. 6, No. 4, 2007, pp. 211-224. doi:10.2463/mrms.6.211
[40] S. Kobayashi, F. Koga, S. Yoshida, et al., “Diagnostic Performance of Diffusion-Weighted Magnetic Resonance Imaging in Bladder Cancer: Potential Utility of Apparent Diffusion Coefficient Values as a Biomarker to Predict Clinical Aggressiveness,” European Radiology, Vol. 21, No. 10, 2011, pp. 2178-2186. doi:10.1007/s00330-011-2174-7
[41] J. B. Unger, J. J. Ivy, M. R. Ramaswamy, et al., “WholeBody [18F]Fluoro-2-Deoxyglucose Positron Emission Tomography Scan Staging Prior to Planned Radical Hysterectomy and Pelvic Lymphadenectomy,” International Journal of Gynecological Cancer, Vol. 15, No. 6, 2005, pp. 1060-1064. doi:10.1111/j.1525-1438.2005.00262.x
[42] B. H. Bochner, D. Cho, H. W. Herr, et al., “Prospectively Packaged Lymph Node Dissections with Radical Cystectomy: Evaluation of Node Count Variability and Node Mapping,” Journal of Urology, Vol. 172, No. 4, 2004, pp. 1286-1290.
[43] J. O. Barentsz, M. R. Engelbrecht, J. A. Witjes, et al., “MR Imaging of the Male Pelvis,” European Radiology, Vol. 9, No. 9, 1999, pp. 1722-1736. doi:10.1007/s003300050916
[44] R. E. Dorfman, M. B. Alpern, B. H. Gross, et al., “Upper Abdominal Lymph Nodes: Criteria for Normal Size Determined with CT,” Radiology, Vol. 180, No. 2, 1991, pp. 319-322.
[45] A. Saokar, T. Islam, M. Jantsch, et al., “Detection of Lymph Nodes in Pelvic Malignancies with Computed Tomography and Magnetic Resonance Imaging,” Clinical Imaging, Vol. 34, No. 5, 2010, pp. 361-366. doi:10.1016/j.clinimag.2009.07.004
[46] T. K. Jensen, P. Holt, O. Gerke, et al., “Preoperative Lymph-Node Staging of Invasive Urothelial Bladder Cancer with 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Axial Tomography and Magnetic Resonance Imaging: Correlation with Histopathology,” Scandinavian Journal of Urology, Vol. 45, No. 2, 2011, pp. 122-128. doi:10.3109/00365599.2010.544672
[47] W. M. Deserno, M. G. Harisinghani, M. Taupitz, et al., “Urinary Bladder Cancer: Preoperative Nodal Staging with Ferumoxtran-10-Enhanced MR Imaging,” Radiology, Vol. 233, No. 2, 2004, pp. 449-456. doi:10.1148/radiol.2332031111
[48] H. C. Thoeny, M. Triantafyllou, F. D. Birkhaeuser, et al., “Combined Ultrasmall Superparamagnetic Particles of Iron Oxide-Enhanced and Diffusion-Weighted Magnetic Resonance Imaging Reliably Detect Pelvic Lymph Node Metastases in Normal-Sized Nodes of Bladder and Prostate Cancer Patients,” European Urology, Vol. 55, No. 4, 2009, pp. 761-769. doi:10.1016/j.eururo.2008.12.034
[49] R. Papalia, G. Simone, R. Grasso, et al., “Diffusion-Weighted Magnetic Resonance Imaging in Patients Selected for Radical Cystectomy: Detection Rate of Pelvic Lymph Node Metastases,” BJUI International, Vol. 109, No. 7, 2012, pp. 1031-1036. doi:10.1111/j.1464-410X.2011.10446.x
[50] R. Montironi and A. Lopez-Beltran, “The 2004 WHO Classification of Bladder Tumors: A Summary and Commentary,” International Journal of Surgical Pathology, Vol. 13, No. 2, 2005, pp. 143-153. doi:10.1177/106689690501300203
[51] M. Housset, C. Maulard, Y. Chretien, et al., “Combined Radiation and Chemotherapy for Invasive TransitionalCell Carcinoma of the Bladder: A Prospective Study,” Journal of Clinical Oncology, Vol. 11, No. 11, 1993, pp. 2150-2157.
[52] C. Rodel, C. Weiss and R. Sauer, “Trimodality Treatment and Selective Organ Preservation for Bladder Cancer,” Journal of Clinical Oncology, Vol. 24, No. 35, 2006, pp. 5536-5544. doi:10.1200/JCO.2006. 07.6729
[53] W. U. Shipley, D. S. Kaufman, E. Zehr, et al., “Selective Bladder Preservation by Combined Modality Protocol Treatment: Long-Term Outcomes of 190 Patients with Invasive Bladder Cancer,” Urology, Vol. 60, No. 1, 2002, pp. 62-68.
[54] P. W. Chung, R. G. Bristow, M. F. Milosevic, et al., “LongTerm Outcome of Radiation-Based Conservation Therapy for Invasive Bladder Cancer,” Urologic Oncology, Vol. 25, No. 4, 2007, pp. 303-309. doi:10.1016/j.urolonc.2006.09.015
[55] M. J. Dobson, B. M. Carrington, C. D. Collins, et al., “The Assessment of Irradiated Bladder Carcinoma Using Dynamic Contrast-Enhanced MR Imaging,” Clinical Radiology, Vol. 56, No. 2, 2001, pp. 94-98. doi:10.1053/crad.2000.0560
[56] P. Therasse, S. G. Arbuck, E. A. Eisenhauer, et al., “New Guidelines to Evaluate the Response to Treatment in Solid Tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada,” Journal of the National Cancer Institute, Vol. 92, No. 3, 2000, pp. 205-216. doi:10.1093/jnci/92.3.205
[57] R. J. Johnson, B. M. Carrington, J. P. Jenkins, et al., “Accuracy in Staging Carcinoma of the Bladder by Magnetic Resonance Imaging,” Clinical Radiology, Vol. 41, No. 4, 1990, pp. 258-263. doi:10.1016/S0009-9260(05)81661-7
[58] A. El-Assmy, M. E. Abou-El-Ghar, H F. Refaie, et al., “Diffusion-Weighted Magnetic Resonance Imaging in Follow-Up of Superficial Urinary Bladder Carcinoma after Transurethral Resection: Initial Experience,” BJUI Internationa, Vol. 110, No. 11b, 2012, pp. E622-E627. doi:10.1111/j.1464-410X.2012.11345.x
[59] S. Yoshida, F. Koga, S. Kawakami, et al., “Initial Experience of Diffusion-Weighted Magnetic Resonance Imaging to Assess Therapeutic Response to Induction Chemoradiotherapy against Muscle-Invasive Bladder Cancer,” Urology, Vol. 75, No. 2, 2010, pp. 387-391. doi:10.1016/j.urology. 2009.06.111

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.